reports
Achillion Shareholders Approve Agreement to be Acquired by Alexion
Achillion Shareholders Approve Agreement to be Acquired by Alexion BLUE BELL, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that its shareholders have approved the acquisition of Achillion by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN). Achillion continues to expect the transaction to close in the first half of 2020, subject to expiration or termination of the applicable waiting period un...
Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4...
Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting – 2.4 g/dL mean increase in hemoglobin at 24 weeks –– Reduction in blood transfusions from 34 to 1; and improvements in markers of hemolysis –- Completed End of Phase 2 Meeting; Phase 3 Trial Initiation in early 2020 - BLUE BELL, Pa., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company de...
Increased risk weighs on ACHILLION PHARMS.INCO., penalising its ratin...
The independent financial analyst theScreener just lowered the general evaluation of ACHILLION PHARMS.INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 2 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date December 6, 2019, the c...
- Wedbush Research
SHOP SHOPIFY INC.
INFY INFOSYS LIMITED
ADS ADIDAS AG
ACN ACCENTURE PLC CLASS A
WWW WOLVERINE WORLD WIDE INC.
WSM WILLIAMS-SONOMA INC.
W9N WNS (HOLDINGS) LIMITED SPONSORED ADR
WIX WIX.COM LTD.
WITN WIPRO LTD
TXRH TEXAS ROADHOUSE INC.
TSLA TESLA INC
SQ SQUARE INC. CLASS A
SPLK SPLUNK INC.
SHOO STEVEN MADDEN LTD.
ROST ROSS STORES INC.
KSS KOHL'S CORPORATION
JWN NORDSTROM INC.
JACK JACK IN THE BOX INC.
ICPT INTERCEPT PHARMACEUTICALS INC.
GPS GAP INC.
GDDY GODADDY INC. CLASS A
35G GENPACT LIMITED
EXLS EXLSERVICE HOLDINGS INC.
EPAM EPAM SYSTEMS INC.
DIN DINE BRANDS GLOBAL INC.
CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION CLASS A
CHUY CHUY'S HOLDINGS INC.
CAL CALERES INC.
BIIB BIOGEN INC.
ALXN ALEXION PHARMACEUTICALS INC.
AEO AMERICAN EAGLE OUTFITTERS INC.
ACHN ACHILLION PHARMACEUTICALS INC.
BJRI BJ'S RESTAURANTS INC.
PUM PUMA EXPLORATION INC.
DRI DARDEN RESTAURANTS INC.
GLOB GLOBANT SA
SCVL SHOE CARNIVAL INC.
VFC V.F. CORPORATION
BHVN BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
NKE NIKE INC. CLASS B
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
CAKE THE CHEESECAKE FACTORY
TJX THE TJX COMPANIES
RGLS REGULUS THERAPEUTICS
PLCE THE CHILDREN'S PLACE
URBN INC.
URBAN JAKARTA PROPERTINDO
- Laura Chico
European Medicines Agency Grants PRIME Designation to Danicopan for Tr...
European Medicines Agency Grants PRIME Designation to Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Not Adequately Responding to a C5 Inhibitor – Phase 3 PNH initiation planned early 2020 – BLUE BELL, Pa., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the European Medicines Agency (EMA) has granted access to support through the PRIME (PRIority MEdicines)...
Achillion Announces Clearance of Investigational New Drug Application ...
Achillion Announces Clearance of Investigational New Drug Application for ACH-5228 BLUE BELL, Pa., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has reviewed and cleared the Investigational New Drug Application (IND) for ACH-5228, the Company’s second-generation oral factor D inhibitor. The opening IND study in the United States will be a drug-dr...
Achillion Reports Third Quarter 2019 Financial Results and Provides Co...
Achillion Reports Third Quarter 2019 Financial Results and Provides Corporate Update – Reached an agreement to be acquired by Alexion; transaction expected to close in first half of 2020 – – Danicopan (ACH-4471) received Breakthrough Therapy designation for treatment of PNH; Phase 2 combination trial top-line results to be presented at 61st ASH Annual Meeting – – ACH-5228 Phase 1 MAD study completed; Phase 2 trial initiation planned for first half of 2020 – – Cash and securities of $229.0 million as of September 30, 2019; projected Year-End Cash ...
Achillion Announces Data Presentations at the 61st American Society of...
Achillion Announces Data Presentations at the 61st American Society of Hematology Annual Meeting BLUE BELL, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced the acceptance of two abstracts about danicopan, the Company’s lead oral factor D inhibitor, for poster presentation at the 61st American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida from December 7-10, 2019. ...
Achillion to Present at the 2019 Cantor Fitzgerald Global Healthcare C...
Achillion to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference BLUE BELL, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Joseph Truitt, President and Chief Executive Officer of Achillion will present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Thursday, October 3, 2019, at 8:55 a.m. ET at the InterContinental New York Barclay in New York, NY. The l...
Achillion Receives Breakthrough Therapy Designation from FDA for Danic...
Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria – Danicopan Phase 2 PNH combination therapy topline data expected Q4 2019 –– Initiation of Phase 3 planned for early 2020 – BLUE BELL, Pa., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
Achillion to Present at the Baird 2019 Global Healthcare Conference
Achillion to Present at the Baird 2019 Global Healthcare Conference BLUE BELL, Pa., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Joseph Truitt, President and Chief Executive Officer of Achillion will present at the Baird 2019 Global Healthcare Conference on Thursday, September 5, 2019, at 12:50 p.m. ET at the InterContinental New York Barclay in New York, NY. The live audio and subsequen...
Achillion Reports Second Quarter 2019 Financial Results and Provides C...
Achillion Reports Second Quarter 2019 Financial Results and Provides Corporate Update – Danicopan (ACH-4471) Phase 2 combination therapy interim data showed clinically meaningful improvements in laboratory parameters of PNH; End-of-Phase 2 meeting activities initiated with FDA – – ACH-5228’s near complete and sustained inhibition of the alternative pathway and its tolerability support US IND submission Q4 2019 – – Cash and securities of $241.3 million as of June 30, 2019 – BLUE BELL, Pa., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN...
Achillion’s ACH-5228 Achieves Positive Results in Phase 1 Multiple A...
Achillion’s ACH-5228 Achieves Positive Results in Phase 1 Multiple Ascending Dose Study in Healthy Volunteers ACH-5228 delivers near complete and sustained inhibition of the complement alternative pathway Twice-daily oral administration to move forward in Phase 2 trials Investigational New Drug (IND) application to be submitted in fourth quarter of 2019 BLUE BELL, Pa., July 22, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated dise...
Achillion to Present at the JMP Securities Life Sciences Conference
Achillion to Present at the JMP Securities Life Sciences Conference BLUE BELL, Pa., June 13, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Brian Di Donato, Chief Financial Officer and Steven Zelenkofske, D.O., Chief Medical Officer of Achillion will present at the JMP Securities Life Sciences Conference on Thursday, June 20, 2019, at 11:00 a.m. ET at the St. Regis New York in New York, NY. The liv...
Achillion Announces Upcoming Scientific Presentation at the 24th Congr...
Achillion Announces Upcoming Scientific Presentation at the 24th Congress of the European Hematology Association BLUE BELL, Pa., June 10, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the final data set for ACH-4471 (newly designated “danicopan”) proof of concept Phase 2 trial in untreated patients with paroxysmal nocturnal hemoglobinuria (PNH) was accepted for oral presentation at the 24th Congre...
Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combinati...
Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting - ACH-4471 increased hemoglobin and nearly eliminated the need for transfusions in patients with PNH being treated with C5 inhibitor, eculizumab - BLUE BELL, Pa., May 17, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today reported interim data from a Phase 2 paroxysmal noctu...
Achillion Granted Twentieth Patent for Factor D Portfolio
Achillion Granted Twentieth Patent for Factor D Portfolio USPTO grants composition of matter patent for ACH-5548, Achillion’s 3rd clinical-stage asset BLUE BELL, Pa., May 14, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) ), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent #10,287,301 to Achillion for ACH-5548, its next-generation orally administered complement factor D small molecul...
Achillion Reports First Quarter 2019 Financial Results
Achillion Reports First Quarter 2019 Financial Results - PNH combo Phase 2 trial interim data to be presented May 17, 2019 -- C3G Phase 2 trials 24 patients enrolled as of May 2019 - - Next-generation ACH-5228 planned U.S. IND submission Q4:2019 -- Cash and securities of $254 million as of March 31, 2019 - BLUE BELL, Pa., May 09, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today reported its financial results for t...
Achillion Announces Enrollment Milestone in Phase 2 Trials for C3 Glom...
Achillion Announces Enrollment Milestone in Phase 2 Trials for C3 Glomerulopathy - Enrolled 23 patients in ACH-4471 Phase 2 C3G six and 12-month clinical trials -- Targeting end-of-Phase 2 meeting with FDA in fourth quarter of 2019 - BLUE BELL, Pa., April 03, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that it achieved threshold enrollment in the Phase 2 trials of ACH-4471 for patients with C3 gl...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.